论文部分内容阅读
目的:了解风湿病患者ENA(盐水可提取核抗原)多肽抗体谱,为临床诊断和治疗提供科学依据。方法:应用免疫印迹法(Western-blot)检测了50例风湿病患者(研究组)和60例其他病种患者(对照组)的ENA多肽抗体,并对结果进行比较。结果:对照组中60例患者ENA多肽抗体均为阴性。50例风湿病患者中,37例ENA多肽抗体阳性,总阳性率为74%,其中SLE患者抗Sm、抗u1RNP和抗Rib阳性率分别为61.5%、46.2%和30.8%;MCTD患者抗u1RNP阳性率为52.9%;PSS患者抗Scl-70阳性率为55.6%;SS患者抗ss A、抗ss B阳性率分别为66.7%、50.0%。结论:ENA多肽抗体在风湿病患者中检出率较高,对临床诊断和治疗具有非常重要的意义。
OBJECTIVE: To understand the antibody spectrum of ENA (salt extractable nuclear antigen) polypeptide in patients with rheumatism and provide a scientific basis for clinical diagnosis and treatment. Methods: The ENA peptide antibodies of 50 patients with rheumatic diseases (study group) and 60 patients with other diseases (control group) were detected by Western-blot and the results were compared. Results: The control group of 60 patients with ENA polypeptide antibodies were negative. Of the 50 patients with rheumatic diseases, 37 were positive for ENA peptide antibody with a total positive rate of 74%. The positive rates of anti-Sm, anti-u1RNP and anti-Rib in SLE patients were 61.5%, 46.2% and 30.8%, respectively. The positive rates of anti-u1RNP in MCTD patients The positive rate of anti-Scl-70 in patients with PSS was 55.6%. The positive rates of anti-ss A and anti-ss B in patients with SS were 66.7% and 50.0%, respectively. Conclusion: The detection rate of ENA peptide antibody in patients with rheumatism is very high, which is of great significance for clinical diagnosis and treatment.